Loading
PSMC3 (26S proteasome regulatory subunit 6A) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.38, genetic association 0.04, clinical 0.99).
In plain words · PSMC3 (26S proteasome regulatory subunit 6A) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
PSMC3 (26S proteasome regulatory subunit 6A) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins.
No product in this corpus aims at PSMC3 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists PSMC3 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA PSMC3: RNA low tissue specificity; high antibody staining in 28 normal tissues; highest cancer staining lymphoma (9 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas PSMC3 tissue; Open Targets ENSG00000165916 associations
First described 1990. Earliest sequence paper UniProt cites for the protein: Nelbock et al, Science, 1990, "A cDNA for a protein that interacts with the human immunodeficiency virus Tat transactivator". Source.
Sources: HGNC HGNC:9549 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P17980 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000165916 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: plasma cell myeloma 0.60, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0))
Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. PSMC3 belongs to the heterohexameric ring of AAA (ATPases associated with diverse cellular activities) proteins that unfolds ubiquitinated target proteins that are concurrently translocated into a proteolytic chamber and degraded into peptides. Location: Cytoplasm; Nucleus (UniProt). Locus 11p11.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Appendix, Breast, Endometrium, Epididymis, Heart muscle, Liver, Lymph node, Oral mucosa.
Medium only: carcinoid, cervical cancer, head and neck cancer, liver cancer.
HPA PSMC3 tissue · HPA PSMC3 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PSMC3" OR ABSTRACT:"PSMC3" OR TITLE:"proteasome 26S subunit, ATPase 3" OR ABSTRACT:"proteasome 26S subunit, ATPase 3" OR TITLE:"26S proteasome regulatory subunit 6A" OR ABSTRACT:"26S proteasome regulatory subunit 6A" OR TITLE:"TBP1" OR ABSTRACT:"TBP1" OR TITLE:"TBP-1" OR ABSTRACT:"TBP-1" OR TITLE:"RPT5" OR ABSTRACT:"RPT5") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMC3, not a curated reading list.